Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p>
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Publicado em: |
2025
|
| Assuntos: | |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1849927621930909696 |
|---|---|
| author | Kristoffer Staal Rohrberg (15009138) |
| author2 | Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870) |
| author_role | author |
| dc.creator.none.fl_str_mv | Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870) |
| dc.date.none.fl_str_mv | 2025-11-26T07:40:31Z |
| dc.identifier.none.fl_str_mv | 10.1158/2767-9764.30719286 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_2_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719286 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas |
| dc.title.none.fl_str_mv | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_3745c53dd23310cbf4fce301263bd882 |
| identifier_str_mv | 10.1158/2767-9764.30719286 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30719286 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg (15009138)Juanita S. Lopez (22687839)Mohammed M. Milhem (15352499)Christian U. Blank (14850778)Irene Reijers (22687842)Fiona Thistlethwaite (22687845)Ruth Plummer (15028641)Sarina A. Piha-Paul (15294428)Pasi A. Jänne (14954872)Elaine Shum (14955138)Heather M. Shaw (22687848)Philip R. Debruyne (20432881)Cristopher Lao (22687851)Jean-Francois Baurain (15031089)Jennifer H. Choe (15052775)Eelke Gort (17740951)Yujie Zhao (22687854)Guy Jerusalem (15017648)Patrick Schöffski (15013461)Andrew William Chen (22687857)Eric A. Cohen (15017996)Walter C. Mankowski (22687860)Leonid Roshkovan (22687863)Sharyn I. Katz (22687866)Despina Kontos (15018005)Lauren K. Brady (22687869)Mohammed Qutaish (22687872)Patricia Garrido Castro (22687875)Nora Pencheva (22687878)Gaurav Bajaj (22687881)Yali Fu (22687884)Kristian Windfeld (22687887)Panagiota Reiter (22687890)Maria Jure-Kunkel (15117740)Brandon W. Higgs (15035279)Katayoun I. Amiri (22687893)Tahamtan Ahmadi (22687896)Ulf Forssmann (22687899)Suresh S. Ramalingam (14951413)Ignace Vergote (15027870)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsImmunologyAntibodies/immunoconjugatesLung CancerMelanomaOvarian CancerSarcomas<p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p>2025-11-26T07:40:31ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30719286https://figshare.com/articles/figure/Figure_2_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719286CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307192862025-11-26T07:40:31Z |
| spellingShingle | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Kristoffer Staal Rohrberg (15009138) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas |
| status_str | publishedVersion |
| title | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_full | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_fullStr | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_full_unstemmed | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_short | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_sort | Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas |